Pacira BioSciences (PCRX) Debt to Equity (2010 - 2026)

Pacira BioSciences' Debt to Equity history runs 15 years deep, the most recent figure standing at $0.56 for Q1 2026.

• In Q1 2026, Debt to Equity rose 47.9% year-over-year to $0.56; the TTM figure through Mar 2026 stood at $0.56 (up 47.9% YoY), while the FY2025 annual figure was $0.54, down 28.59% from the prior year.
• Debt to Equity was $0.56 for Q1 2026 at Pacira BioSciences, up from $0.54 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.75 in Q4 2024 to a low of $0.12 in Q2 2024.
• Historically, Debt to Equity has averaged $0.37 across 5 years, with a median of $0.4 in 2025.
• The sharpest annual moves came in 2023 and 2024: Debt to Equity sank 68.22% in 2023, then soared 428.36% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.37 in 2022, then tumbled by 61.26% to $0.14 in 2023, then soared by 428.36% to $0.75 in 2024, then dropped by 28.59% to $0.54 in 2025, then advanced by 4.71% to $0.56 in 2026.
• The last three Debt to Equity figures came in at $0.56 (Q1 2026), $0.54 (Q4 2025), and $0.52 (Q3 2025), per Business Quant data.